Renovia Inc. has recently closed on $32 million of Series B funding to go ahead with new products treat pelvic floor disorders. The company, which was co-founded by Marc Beer in 2016, also received $10 million in venture capital as well.
The funds will be used to develop four new products addressing pelvic floor ailments, though details were not released by the company. Bizjournals.com said they will address diagnostic and therapeutic improvements that address ailments that may include urinary incontinence. Marc Beer said in a statement the company aims to improve its sensor technology to give healthcare providers the tools to incorporate better data in their treatment strategies. Beer went on to say that these improvements will “eventually” bring down healthcare costs.
The Series B included money from the Longwood Fund, which was an early investor in the Beer’s co-founded company. The Series B process was led by Perspective Advisors, based out of New York, and Missouri-based Ascension Ventures. Renovia Inc. developed the drug Leva, which was approved by the FDA back in April. The Series B funding will partly be used will be used to create a new generation of Leva, it was said in the bizjournals.com article.
Marc Beers joined two others, Ramon Iglesias and Yolanda Lorie, to create Renovia in August 2016 and was instrumental in securing the Series A funding used to develop Leva. The Longwood fund was one of those initial investors. Marc Beers co-founded Renovia Inc. after a long tenure in the medical field, has commercialized a number of products in the areas of biotechnology, pharmaceuticals, devices and diagnostics.
Among other companies he started was ViaCell, a biotechnology company that focuses on the collection, preservation, and development of umbilical cord stem cells. He led the company from inception to its growth to 300 employees to ts eventual sale to PerkinElmer in 2007. Prior to that, Marc Beers was a member of the board of directors of Erytech Pharma and held positions with Genzyme where he served most recently as the vice president of global marketing where he was instrumental in the launch of drugs addressing rare diseases across the globe. Learn more: https://renoviainc.com/leadership/
Marc Beer has extensive experience and expertise in commercialization and development in pharmaceuticals, diagnostics, devices, and biotechnology. Marc Beer cofounded Revonia alongside Yolanda Lorie, MD, and Ramon Iglesias in August 2016. The company has successfully achieved a Series A Financing with top healthcare business capital funds since its creation in 2016.
Marc Beer was appointed the Founding Chief Executive Officer of ViaCell in April 2010. ViaCell is a biotechnology firm that focuses on the activities that are involved in the collection, preservation, and development of blood stem cells of the human umbilical cord. Marc Beer led the management of ViaCell for over seven years. He helped the company to grow from its inception to become one of the rapidly growing firms with the intense commercialization of its products and services.
Marc Beer’s leadership and management of ViaCell helped it to go public in 2005, developed to offer over 300 job opportunities, and later purchased by PerkinElmer in the year 2007. Marc Beer dedicated his time and skills to ensure that he used his position as the CEO of the ViaCell to propel it from its humble beginning to attaining international standards.
Marc Beer was also a Board member of the Board of Directors of Erytech Pharma. Erytech Pharma is a publicly traded company that provides pharmaceutical products and services. He was key personnel in the board as he represented the firm in a variety of development forums. Marc Beer also held a variety of positions in Genzyme. One of the most recent post that Mr. Marc held within Genzyme was that of the Vice President of Global Marketing. Under this rank, Mr. Marc Beer was tasked with the responsibilities of the commercial launching of various products that addressed several rare diseases that affected populations around the globe.
Before joining Genzyme, Marc spent years serving Abbott Laboratories where he held various roles in sales and marketing in the diagnostic and pharmaceutical divisions. Marc was also in the Mass Life Science Board of the Massachusetts Commonwealth. He worked in the Emerging Companies Section Governing Board of the Biotechnology Industry Organization.
Marc Beer was among the founders and Founding Chairman of the Board of directors of Good Start Genetics, Inc. He was also the Chairman of the compensation committee of the organization. The Good Start Genetics, Inc. was purchased by InVatae Company just recently. Marc Beer also played some vital roles in the foundation of Minerva Neurosciences, Inc. Learn more: https://www.bizjournals.com/boston/potmsearch/detail/submission/6457372/Marc_Beer